LIXIANA DIN 02458659
Status: Cancelled Post Market
Holder: SERVIER CANADA INC
Molecule: EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE)
Available to quote
Health Canada record
| Active ingredient(s) | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 30 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | B01AF03 EDOXABAN |
| Original market date | 25-Apr-2017 |
| Current status date | 24-Feb-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Servier Canada Inc — licence 100542, currently licensed, last inspection rating C (2023-05-31).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02566389 | AG-EDOXABAN | ANGITA PHARMA INC. | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 60 MG | Approved |
| 02566370 | AG-EDOXABAN | ANGITA PHARMA INC. | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 30 MG | Approved |
| 02566362 | AG-EDOXABAN | ANGITA PHARMA INC. | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 15 MG | Approved |
| 02561662 | GLN-EDOXABAN | GLENMARK PHARMACEUTICALS CANADA INC. | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 15 MG | Approved |
| 02561689 | GLN-EDOXABAN | GLENMARK PHARMACEUTICALS CANADA INC. | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 60 MG | Approved |
| 02561670 | GLN-EDOXABAN | GLENMARK PHARMACEUTICALS CANADA INC. | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 30 MG | Approved |
| 02557290 | JAMP EDOXABAN | JAMP PHARMA CORPORATION | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 60 MG | Marketed |
| 02557274 | JAMP EDOXABAN | JAMP PHARMA CORPORATION | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 15 MG | Approved |
| 02557282 | JAMP EDOXABAN | JAMP PHARMA CORPORATION | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 30 MG | Marketed |
| 02563150 | PMS-EDOXABAN | PHARMASCIENCE INC | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 30 MG | Approved |
| 02563142 | PMS-EDOXABAN | PHARMASCIENCE INC | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 15 MG | Approved |
| 02563169 | PMS-EDOXABAN | PHARMASCIENCE INC | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 60 MG | Approved |
| 02556960 | PRO-EDOXABAN | PRO DOC LIMITEE | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 30 MG | Marketed |
| 02556979 | PRO-EDOXABAN | PRO DOC LIMITEE | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 60 MG | Marketed |
| 02556952 | PRO-EDOXABAN | PRO DOC LIMITEE | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 15 MG | Approved |
| 02557614 | REDDY-EDOXABAN | DR REDDY'S LABORATORIES LTD | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 30 MG | Approved |
| 02557622 | REDDY-EDOXABAN | DR REDDY'S LABORATORIES LTD | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 60 MG | Approved |
| 02557606 | REDDY-EDOXABAN | DR REDDY'S LABORATORIES LTD | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 15 MG | Approved |
| 02553414 | SANDOZ EDOXABAN | SANDOZ CANADA INCORPORATED | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 15 MG | Marketed |
| 02553430 | SANDOZ EDOXABAN | SANDOZ CANADA INCORPORATED | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 60 MG | Marketed |
| 02553422 | SANDOZ EDOXABAN | SANDOZ CANADA INCORPORATED | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 30 MG | Marketed |
| 02554216 | TEVA-EDOXABAN | TEVA CANADA LIMITED | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 30 MG | Marketed |
| 02554224 | TEVA-EDOXABAN | TEVA CANADA LIMITED | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 60 MG | Marketed |
| 02554208 | TEVA-EDOXABAN | TEVA CANADA LIMITED | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 15 MG | Marketed |
| 02458667 | LIXIANA | SERVIER CANADA INC | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 60 MG | Cancelled Post Market |
| 02458640 | LIXIANA | SERVIER CANADA INC | Tablet | EDOXABAN (EDOXABAN TOSYLATE MONOHYDRATE) 15 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 18635 | 2016-11-04 | New Drug Submission (NDS) |